Key result
Patients with RV cardiomyopathy of unknown source undergoing ablation had more favorable VT-free survival (71%) compared to those with ARVC/D (60%) or cardiac sarcoidosis (41%) (P=0.03).
Why the study?
What are the electrophysiologic characteristics and ablation outcomes of patients with right ventricular scar-related ventricular tachycardia of unknown source compared to ARVC/D and cardiac sarcoidosis?
Observational (n=100)
What are the electrophysiologic characteristics and ablation outcomes of patients with right ventricular scar-related ventricular tachycardia of unknown source compared to ARVC/D and cardiac sarcoidosis?
p-value: p=0.03
Patients with right ventricular scar-related VT of unknown source (RCUS) have a more favorable prognosis post-ablation compared to those with ARVC/D or cardiac sarcoidosis.
Supports etiology-specific prognosis counseling after RV VT ablation; hypothesis-generating, needs prospective validation before guiding practice.
BACKGROUND: Right ventricular (RV)-scar related ventricular tachycardia (VT) is often due to arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) or cardiac sarcoidosis (CS), but some patients whose clinical course has not been described do not fulfill diagnostic criteria for these diseases. We sought to characterize the electrophysiologic substrate and catheter ablation outcomes of such patients, termed RV cardiomyopathy of unknown source (RCUS). METHODS AND RESULTS: Data of 100 consecutive patients who presented with RV cardiomyopathy and/or RV-related VT for ablation were reviewed (51 ARVC/D, 22 CS; 27 RCUS). Compared to ARVC/D, RCUS patients were older (P = 0.001), less commonly had RV dilatation (P = 0.001) or dysfunction (P = 0.01) and fragmented QRS, parietal block, and T-wave inversion. Compared to CS, R-CUS patients had less severe LV dysfunction. Extent and distribution of endocardial/epicardial scar and inducible VTs in RCUS patients were comparable with ARVC/D and CS patients. At a median follow-up of 23 months, RCUS patients had more favorable VT-free survival (RCUS 71%, ARVC/D 60%, CS 41%, P = 0.03) and survival free of death or cardiac transplant (RCUS 92%, ARVC/D 92%, CS 62%, P = 0.01). No RCUS patients developed new criteria for ARVC/D or CS in follow-up. CONCLUSIONS: Up to one-third of patients with RV scar-related VT are not classifiable as ARVC/D or CS. These patients had a somewhat better prognosis than ARVC/D or sarcoid and did not develop evidence of these diseases during the initial 2 years of follow-up. The extent to which this population comprises mild ARVC/D, CS, or other diseases is not clear.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2017) conducted an observational in Right ventricular scar-related ventricular tachycardia (n=100). Catheter ablation in RV cardiomyopathy of unknown source (RCUS) vs. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) and cardiac sarcoidosis (CS) was evaluated on VT-free survival (p=0.03). Patients with RV cardiomyopathy of unknown source undergoing ablation had more favorable VT-free survival (71%) compared to those with ARVC/D (60%) or cardiac sarcoidosis (41%) (P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: